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Interleukin-18 is a novel cytokine identi®ed as a
strong inducer of interferon-g. Interleukin-18 has
been shown to have similar bioactivities to interleu-
kin-12 and to have antitumor ef®cacy in experimen-
tal models. In this study, we investigated whether
the introduction of the interleukin-18 gene to
B16F10 melanoma cells can induce antitumor
response or not. Before the transfection, we modi®ed
the interleukin-18 gene to enable transfected tumor
cells to secrete bioactive interleukin-18, because
interleukin-18 does not have a signal sequence and
requires processing by the interleukin-1 converting
enzyme to attain the mature form. We found that
B16 melanoma cells transduced with hybrid cDNA
consisting of the interferon-b signal sequence and
mature interleukin-18 sequence, but not native inter-
leukin-18, secreted a large amount of interleukin-18
and exhibited retarded tumor growth when injected
in syngeneic mice. The antitumor effect was mostly
abrogated by administration of anti-interferon-g anti-
body, but was not affected by in vivo depletion of
CD8+ T cells or natural killer cells. Histologic analy-
sis revealed that vascularization was markedly
reduced and that necrosis was extensively induced in
interleukin-18-secreting B16F10 melanoma (B16/
IL18) tissues, whereas abundant tumor vessel forma-
tion was observed in B16/IL18 tissues of interferon-
g-neutralized mice. We also found that chemokines,
interferon-inducible protein-10 and monokine
induced by interferon-g, were produced in B16/IL18
tissues and that the expression of both chemokines
was dependent on that of interferon-g in the tumor
tissues. Further, we showed that B16 melanoma cells
secreted both chemokines in response to interferon-
g. In addition, the expression of angiogenin, an
angiogenic factor of melanoma, in B16 melanoma
cells was reduced by interferon-g treatment. These
results indicate that gene transfer of secreted-type
interleukin-18 to B16F10 melanoma cells is a useful
method of triggering an antitumor response without
any systemic adverse effects and that the antitumor
ef®cacy is mainly mediated by antiangiogenic activ-
ity, which is possibly involved in at least two
dynamic changes induced by interferon-g inside B16
melanoma cells: the upregulation of antiangiogenic
chemokines, interferon-inducible protein-10 and
monokine induced by interferon-g, and the down-
regulation of angiogenic factor, angiogenin. Key
words: angiogenin/gene therapy/IFN-g/interferon-inducible
protein 10 (IP-10)/monokine induced by IFN-g (Mig).
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nterleukin-18 (IL-18) was originally puri®ed, characterized,
and cloned from the liver extracts of mice treated with the
bacterium Propionibacterium acnes and challenged with lipo-
polysaccharide (Okamura et al, 1995). The full-length IL-18
cDNA encodes a precursor of 192 amino acids and a mature
protein of 157 amino acids. The precursor protein is not secreted
due to a lack of signal sequence and has less biologic activity than
the proteolytically processed mature protein. The secretion of
mature protein is dependent on the processing of the precursor
protein by IL-1 converting enzyme (ICE). Recombinant IL-18 was
shown to induce interferon-g (IFN-g) production by stimulated T
cells in the presence of concanavalin A, anti-CD3 monoclonal
antibody, or IL-2. IL-18 also stimulates T cell proliferation and
augments spleen natural killer cell lytic activity in vitro (Okamura et
al, 1995). These biologic actvities are similar to those of IL-12,
which has been demonstrated to have potent immunologic effects
on tumor establishment and metastasis. The antitumor effects of IL-
12 have been well documented in murine studies involving the
administration of either recombinant IL-12 protein (Brunda et al,
1993; Nastala et al, 1994; Mu et al, 1995; Zou et al, 1995),
®broblasts, or tumor cells genetically engineered to secrete IL-12
(Tahara et al, 1994; Martinotti et al, 1995), or IL-12 cDNA
(Rakhmilevich et al, 1996; Tan et al, 1996). The immunologic
similarities between the two cytokines strongly suggest that IL-18
may also be able to induce antitumor immunity. In fact, Micallef et
al (1997) showed that recombinant IL-18 had antitumor effects in a
murine Meth A sarcoma model and that the antitumor immunity
was dependent on natural killer cells and the generation of
cytotoxic CD4+ T cells. Moreover, some investigators have
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recently shown that transduction with IL-18 cDNA to tumor cells
inhibited their growth in vivo (Tan et al, 1998; Heuer et al, 1999;
Tasaki et al, 2000). A murine melanoma cell line B16F10 has many
features that may correspond to the poor immunogenicity of
metastatic tumors in humans, and therefore it has often been
utilized as a target for immunotherapy in experimental animals. The
antitumor effects of IL-18 on B16F10 melanoma have not yet been
evaluated, however. In systemic administration of recombinant IL-
18, there is a limit to the available dose of IL-18 on account of
lethal adverse effects. Though we treated B16F10 melanoma-
loaded mice with the maximum tolerable dose of IL-18, the tumor
growth was not suppressed (Nagai et al, 2000). We speculated that a
suf®cient amount of IL-18 in tumor tissue is indispensable for
inducing an effective antitumor response to B16 melanoma.
Therefore, we introduced the IL-18 gene into B16F10 melanoma
cells, in an attempt to induce an effective antitumor response
without the adverse effects. There exists a problem in introducing
the IL-18 gene into tumor cells, however. As IL-18 does not have a
signal sequence and requires processing by ICE to attain a mature
form, bioactive IL-18 cannot be secreted even if native IL-18
cDNA is introduced into tumor cells. To solve this problem, we
constructed a hybrid cDNA consisting of the IFN-b signal
sequence and mature IL-18 sequence using an overlap extension
method. We transduced B16 melanoma cells with the hybrid
cDNA, and succeeded in establishing B16 melanoma clones that
secrete a large amount of IL-18.
MATERIALS AND METHODS
Tumor cell lines The melanoma cell line B16F10 of C57BL/6 mouse
origin was maintained in Eagle's modi®ed essential medium
supplemented with 5% heat-inactivated fetal bovine serum (FBS) at 37°C
in a humidi®ed atmosphere of 5% CO2/air.
Modi®cation of mouse IL-18 cDNA for transfection Native IL-18
(192 amino acids) does not have bioactivity, whereas mature IL-18 (157
amino acids) processed from native IL-18 does. As IL-18 cDNA does
not have a signal sequence, it requires ICE for processing. To enable
transfected tumor cells to secrete bioactive IL-18, we constructed a
hybrid cDNA composed of a signal sequence derived from mouse IFN-b
and a mature IL-18 sequence by the overlap extension method. The
primers used were as follows: no. 1, 5¢-ACACCAGCCTGGCTTCC-
ATCATGAACAACA-3¢; no. 2, 5¢-CCTCCCCACCTAACTTTGAT-
GTAAGTTAGT-3¢; no. 3, 5¢-AGCCCTCTCCAACTTTGGCCGAC-
TTCACTG-3¢; no. 4, 5¢-GGCCAAAGTTGGAGAGGGCTGTGGT-
GGAGA-3¢. The mouse cDNA library was ampli®ed by polymerase
chain reaction (PCR) with primers 1 and 4 to obtain the IFN-b signal
sequence. Mouse IL-18 cDNA clone (pMuGF37B-5) was ampli®ed by
PCR with primers 2 and 3 to obtain the mature IL-18 sequence. Thirty-
®ve cycles of PCR using rTth DNA polymerase (Perkin-Elmer, New
Jersey, NJ) were performed. The two resultant PCR products were
mixed and heated to 94°C for 3 min, then gradually cooled to 37°C
over 1 h, and incubated at 37°C for 15 min. As a result, the two PCR
products annealed at the common sequence of primers 3 and 4
(underlined sequence). rTth DNA polymerase was added and gradually
heated to 72°C to synthesize double stranded DNA. Standard PCR was
then performed with primers 1 and 4. The resultant PCR product was a
hybrid DNA possessing the IFN-b signal sequence and mature IL-18
sequence. The hybrid DNA was cloned into a plasmid vector using a
TA cloning kit (Invitrogen, San Diego, CA).
Expression vector and transfection of tumor cells The expression
vector used in this study (pCEXV3) has been described elsewhere
(Okayama and Berg, 1983). The hybrid DNA, which has the IFN-b
signal sequence and mature IL-18 sequence, was inserted into the Sma I
site of pCEXV3 in the appropriate orientation (pCEXV3/hybrid IL-18).
Native IL-18 cDNA was also inserted into the Sma I site of pCEXV3 in
the appropriate orientation (pCEXV3/native IL-18). Transfection was
performed using LipofectAmine (Gibco BRL, Grand Island, NY). For
drug selection, pSV2neo was cotransfected with these vectors. Brie¯y,
1.8 3 105 B16F10 melanoma cells were plated in 60 mm dishes 1 d
before transfection. Nine micrograms of puri®ed pCEXV3 (as a control),
9 mg of pCEXV3/hybrid IL-18, or 9 mg of pCEXV3/native IL-18 was
cotransfected with 1 mg of puri®ed pSV2neo (Southern and Berg, 1982).
The transfectants were then cloned using geneticin (®nal concentration,
1.5 mg per ml; Sigma, St. Louis, MO).
IL-18 assay To assess IL-18 levels, parental or IL-18 gene-transfected
tumor cells (3.0 3 105) were cultured on six-well plates with 1.5 ml of
modi®ed essential medium supplemented with 5% heat-inactivated FBS,
and the supernatants were collected after 24 h. IL-18 activity was
measured using the sandwich enzyme-linked immunosorbent assay
(ELISA) for IL-18 (Taniguchi et al, 1997) developed by Hayashibara
Biochemical Laboratories (Okayama, Japan).
Cell proliferation assay To compare the in vitro proliferation of
B16F10 sublines, 5 3 103 cells of each cell line were seeded in each well
of six-well plates (9.0 cm2 per well), and the cells in each cell line were
enumerated in triplicate.
Animal studies Speci®c-pathogen-free C57BL/6 mice (6- to 8-wk-
old females) were purchased from CLEA Japan (Tokyo). All animals
were maintained in microisolator cages and exposed to a 12 h light/12 h
dark cycle, with standard feed and water provided ad libitum. All animal
experiments were conducted according to the Guidelines for Animal
Experimentation at Kobe University School of Medicine. Cultured
tumor cells were trypsinized and washed twice with phosphate-buffered
saline (PBS), and 106 cells in 0.1 ml of PBS per mouse were injected
subcutaneously into the right ¯ank of C57BL/6 mice. Each experimental
group consisted of 5±10 mice. The tumor size was measured in
millimeters using calipers every 2±3 d. The longest surface length (a) and
its perpendicular width (b) were measured, and tumor size was reported
as a 3 b. Statistical evaluation of the data was performed using Student's
t test.
Antibody treatments in vivo To deplete CD8+ T cells in vivo, we
intraperitoneally administered rat monoclonal antibody (mAb) 2.43 [anti-
CD8; IgG2b, American Type Culture Collection (ATCC), Rockville,
MD]. This mAb was used as ascites ¯uid (titer > 1:10,000 according to
mouse thymocyte staining by ¯ow cytometry). The mAb preparation
(0.2 ml) was injected intraperitoneally on days ±3, ±2, ±1, and 13 and
every 7 d thereafter. Under these conditions, antibody treatment
depleted > 95% of the CD8+ T cell population in the spleen,
throughout the experiments. Depletion of natural killer cells was
achieved using polyclonal anti-asialo GM1 antibody (Wako Fine
Chemicals, Osaka, Japan). A total of 50 ml of anti-asialo GM1 antibody
diluted with 150 ml of PBS was injected intraperitoneally on day ±1 and
every 5 d thereafter. Depletion of natural killer cells was con®rmed by
4 h 51Cr-release assays with YAC-1 cells as target cells and spleen cells as
effector cells. To neutralize IFN-g activity in vivo, the ascites ¯uid
(0.2 ml) of the R4-6A2 (purchased from the ATCC) rat mAb against
mouse IFN-g was injected intraperitoneally on days ±1, 0, and 1 and
every 7 d thereafter.
Histologic analysis For histologic examination, tissues at the tumor
site and skin were collected 6 d after tumor injection. The resected
tissues were zinc-®xed and embedded in paraf®n, as described previously
(Beckstead, 1994). Hematoxylin±eosin (HE) staining was carried out by
the standard method. Immunohistochemical analysis was performed by
the avidin±biotin complex method using a Vectastain ABC Kit (Vector
Laboratories, Burlingame, CA). The sections were deparaf®nized,
dehydrated, preincubated with bovine serum for blocking, and incubated
with a 1:500 dilution of anti-CD31 mAb (BD PharMingen, San Diego,
CA) followed by biotinylated rabbit antirat IgG[H + L] (Vector
Laboratories). The sections were incubated with 0.03% H2O2 in
methanol for 15 min, and then with horseradish-peroxidase-conjugated
avidin for 45 min. Adsorbed peroxidase was visualized by incubating
with 0.05% 3,3¢-diaminobenzidine (Dojindo Laboratories, Kumamoto,
Japan) for 1±2 min, and counterstained with methylgreen. To detect
IFN-g-producing cells, 6 mm cryostat sections were immunostained with
rat antimouse IFN-g mAb (BD PharMingen).
In vivo angiogenesis assay To evaluate tumor vessel formation, the
tumor tissues resected 6 d after injection were stained with anti-CD31
mAb as described above. Vascularization within the tumors was assessed
by enumerating CD31-positive vessels in ®elds under a microscope. The
counting was performed by two independent observers.
RNA extraction from tumor tissue Tumor cells (1 3 106) in PBS
were inoculated subcutaneously into the right ¯ank of syngeneic mice.
After 6 d, whole tumor tissues were resected and homogenized with
Soni®er 250D (Branson, Kanagawa, Japan). Total cellular RNA was
extracted using acid±guanidinium thiocyanate±phenol±chloroform
(Chomczynski and Sacchi, 1987).
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RNA extraction from B16 melanoma cells treated with murine
IFN-g Tumor cells were plated and cultured in the presence (200 and
1000 U per ml) or absence of recombinant murine IFN-g (Pepro Tech
EC, London, U.K.) for 24 h. Then, tumor cells were collected, and total
cellular RNA was extracted.
Semiquantitative reverse transcription PCR (RT-
PCR) Complementary DNA (cDNA) was synthesized from 5 mg of
total RNA by extension with oligo dT in a 20 ml reaction volume
containing reverse transcription reaction buffer (pH 8.3), 0.01 M
dithiothreitol, 0.5 mM deoxynucleotide phosphate, and 200 U of
Superscript II (Gibco BRL). The mixture was incubated at 37°C for 1 h
and then at 70°C for 15 min.
The presence of cDNA for IL-2, IFN-g, IL-4, and IL-10 was detected
by PCR, using a Quantitative PCRã Detection Kit (Mouse TH1/TH2
Switch Cytokine, BioSource International) according to the manufactur-
er's instructions. Interferon-inducible protein 10 (IP-10) and monokine
induced by IFN-g (Mig) cDNAs were ampli®ed by PCR, using the
following primers described previously (Neumann et al, 1998): IP-10, 5¢-
CCTATCCTGCCCACGTGTTG-3¢ (sense) and 5¢-CGCACCTCCA-
CATAGCTTACA-3¢ (antisense); Mig, 5¢-ATGAAGTCCGCTGTT-
CTTTTCC-3¢ (sense) and 5¢-TTATGTAGTCTTCCTTGAACGAC-3¢
(antisense). Vascular endothelial growth factor (VEGF) and angiogenin
cDNAs were ampli®ed using the following primers: VEGF, 5¢-
GCGGGCTGCCTCGCAGTC-3¢ (sense) and 5¢-TCACCGCCTTG-
GCTTGTCAC-3¢ (antisense); angiogenin, 5¢-CACTCTGGCTCAG-
GATGACT-3¢ (sense) and 5¢-TGACTCATCGAACTGGACCG-3¢
(antisense). PCR was conducted in a Perkin Elmer Cetus Gene Amp
PCR system 9600 (Norwalk, CT) in a 50 ml reaction volume using
Ampli-Taq (Perkin Elmer). Reaction conditions were as follows: 94°C
for 1 min, 63°C for 1 min, and 72°C for 1 min 30 s for 35 cycles (IP-10
and Mig); 94°C for 1 min, 65°C for 1 min, and 72°C for 1 min 30 s for
30 cycles (VEGF); 94°C for 1 min, 65°C for 1 min, and 72°C for 1 min
30 s for 35 cycles (angiogenin).
Nonspeci®c priming and oligomerization were minimized by the hot-
start PCR method. A sample of each reaction (15 ml) was analyzed in
2% agarose gel and visualized by ethidium bromide ¯uorescence staining.
A PCR Markers (Promega, Madison, WI) was used as a molecular
weight marker to estimate the size of fragments.
Direct ELISA To detect both IP-10 and Mig as proteins, a direct
ELISA was performed. B16/P or B16/IL18 cells (4 3 105) were seeded
in each well of six-well plates 1 d before IFN-g treatment. The cells
were incubated in 1 ml of FBS-free Eagle's minimum essential medium
with or without treatment with IFN-g (200 U per ml) for 24 h, and
then the supernatants were collected. The supernatants and standard
solutions containing various concentrations (125.0, 62.5, 31.2, 15.6, 7.8,
3.9, 2.0 ng per ml) of recombinant proteins (murine IP-10 and murine
Mig; Pepro Tech EC) were added to the wells of 96-well plates (Nunc-
ImmunoTM Plate, MaxiSorpTM Surface; NUNC, Roskilde, Denmark),
and then incubated overnight at 4°C. After the incubation, supernatants
and standard solutions were removed. Next, blocking solution (KPL,
Guildford, U.K.) was added to each well, and incubation was continued
for 1.5 h at 37°C. After the wells had been washed, 50 ml of primary
antibody (0.5 mg per ml; antimouse CRG-2 antibody and antimouse
MIG antibody; R&D systems, Minneapolis, MN) was added to each
well; then incubation was continued for 1 h at 37°C. The wells were
washed again, 50 ml of biotinylated secondary antibody (5 mg per ml;
biotinylated antigoat IgG[H + L]; Vector Laboratories) was added to
each, and incubation was continued for 30 min at 37°C. After further
washing, 50 ml of streptavidin alkaline phosphatase (5 mg per ml; Vector
Laboratories) was added to each well, and the plates were incubated 1 h
at room temperature. Finally, 50 ml of pNPP solution (pNPP Microwell
Substrate System; KPL) was added to each well, and then activity was
measured using an ELISA reader (Nippon Bio-Rad Laboratories, Tokyo,
Japan)
RESULTS
IL-18 production by B16 melanoma cells transduced with
the native or modi®ed IL-18 gene IL-18 activities in the
supernatants of B16 melanoma sublines were measured using the
sandwich ELISA method. As expected, B16 melanoma cells
transduced with native IL-18 (B16/native IL-18) did not secrete
detectable amounts of IL-18 into the supernatant, nor did parental
B16 melanoma cells (B16/P) and control-vector-transduced B16
melanoma cells (B16/C). On the other hand, B16 melanoma
clones transduced with hybrid IL-18 (B16/hybrid IL-18) showed
high levels of IL-18 in the culture supernatants. Two clones were
selected as high-level producers of IL-18. The selected clones
(B16/hybrid IL-18 nos. 1 and 2) released 20 and 16 ng per ml of
IL-18, respectively, into the supernatants (data not shown). To
examine whether there is a difference in the proliferation of these
B16 melanoma sublines, we performed in vitro cell proliferation
assays. There was no signi®cant difference in cell proliferation
in vitro among B16/P, B16/C, B16/native IL-18, B16/hybrid IL-
18 no. 1, and B16/hybrid IL-18 no. 2 (Fig 1).
Tumorigenicity of IL-18-transfected B16 melanoma cells in
syngeneic mice To investigate the effects of locally secreted IL-
18 on tumor growth, 106 cells of B16/hybrid IL-18 no. 1, B16/
hybrid IL-18 no. 2, B16/native IL-18, B16/C, and B16/P were
injected into the right ¯ank of syngeneic mice. B16/native IL-18,
B16/P, and B16/C exhibited almost the same degree of tumor
growth (Fig 2). On the other hand, B16/hybrid IL-18 nos.1 and 2
exhibited signi®cant retardation of tumor growth compared with
Figure 1. IL-18 cDNA transfection did not affect B16 melanoma
cell growth in vitro. Cells (5 3 103) of each cell line were seeded in
six-well plates (9.0 cm2 per well) on day 0, and cell numbers were
counted in triplicate on days 2, 4, and 6. Error bars represent standard
deviation. d, B16/P; s, B16/C; h, B16/native IL-18; n, B16/hybrid
IL-18 no. 1; ,, B16/hybrid IL-18 no. 2.
Figure 2. Hybrid IL-18 cDNA-transfected B16 melanoma, but
not native IL-18 cDNA, showed retarded tumor growth in
syngeneic mice. C57/BL6 mice were challenged with B16 parental
melanoma (B16/P), a control-vector-transfected cell line (B16/C), clones
of B16 melanoma transduced with native IL-18 cDNA (B16/native IL-
18) or clones of B16 melanoma transduced with hybrid IL-18 cDNA
(B16/hybrid IL-18 no. 1, B16/hybrid IL-18 no. 2). Mice were injected
subcutaneously with 106 cells in the right ¯ank on day 0. Tumor size
was measured as the product of the longest diameter 3 perpendicular
diameter along with the time course. Data are presented as mean values
in tumor size of ®ve mice per group. Error bars represent standard
deviation. d, B16/P; s, B16/C; h, B16/native IL-18; n, B16/hybrid
IL-18 no. 1; ,, B16/hybrid IL-18 no. 2. *p < 0.01, **p < 0.01
(Student's t test).
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B16/P or B16/C (Fig 2). As B16/hybrid IL-18 no. 1 exhibited a
more pronounced retardation of tumor growth than did B16/
hybrid IL-18 no. 2, B16/hybrid IL-18 no. 1 was used in the
following experiments (hereafter referred to as B16/IL18).
Tumor growth of B16/IL18 in natural-killer- or CD8+ T-
cell-depleted mice To characterize the cells responsible for the
inhibition of tumor growth, tumor-bearing hosts were depleted
in vivo in selected effector-cell populations. Depletion of CD8+ T
cells by anti-CD8 mAb as well as natural killer cells by anti-asialo
GM1 sera did not affect the tumor growth of B16/IL18 (Fig 3).
These results suggest that neither CD8+ T cells nor natural killer
cells are strongly involved in the antitumor effect of locally secreted
IL-18 on B16 melanoma.
Tumor growth of B16/IL18 in syngeneic mice treated with
anti-IFN-g antibody To evaluate whether the antitumor effect
of B16/IL18 is mediated by the induction of IFN-g production by
IL-18, mice injected with B16/IL18 were treated with anti-IFN-g
mAb to neutralize the activity. The neutralization of IFN-g
accelerated the tumor growth of B16/IL18, and resulted in a
signi®cant difference (p < 0.05, Student's t test) with the untreated
group (Fig 4). This result indicates that the antitumor effect of
locally secreted IL-18 on B16 melanoma depends on IFN-g
production.
Histologic analysis To investigate how B16/IL18 was affected
by neutralization of IFN-g, we performed a histologic examination
on the tumor tissues of mice injected with B16/P or B16/IL18 and
of IFN-g-neutralized mice injected with B16/IL18. Throughout all
specimens, we could ®nd no signi®cant differences in mononuclear
cell in®ltration. HE specimens revealed numerous blood vessels in
B16/P tumor tissues (Fig 5a). On the other hand, tumor vessels
were scarcely observed but numerous necrosis and hemorrhage
were found in B16/IL18 tissues (Fig 5b). In B16/IL18 tissues of
IFN-g-neutralized mice, blood-vessel-like structures were observed
as well as B16/P tumors (Fig 5c). We performed immuno-
histochemical staining with anti-CD31 mAb to visualize the
endothelial cells more clearly. We used the zinc-®xation method,
which enabled us to stain immunohistochemically with
morphologic preservation (Beckstead, 1994). Numerous CD31-
positive tumor vessels were clearly observed in specimens of both
B16/P (Fig 5d) and anti-IFN-g-antibody-treated B16/IL18
(Fig 5f), whereas CD31 reacted little with B16/IL18 tissues
(Fig 5e).
Vascularization within tumor tissues To analyze the
vascularization within tumor tissues statistically, the CD31-
positive vessels in tumors were enumerated. As shown in Fig 6,
the number of CD31-positive vessels in the B16/IL18 tumor was
signi®cantly decreased compared with that in B16/P tumors (p
< 0.01). The reduction of tumor vessels in the B16/IL18 tumor was
almost completely halted by treatment with anti-IFN-g antibody (p
< 0.01). The number of CD31-positive vessels was not signi®cantly
different between B16/P tissues and B16/IL18 tissues of IFN-g-
neutralized mice.
Cytokine expression in tumor tissues To investigate the
mechanism of the IFN-g-mediated inhibition of tumor vessel
formation by locally secreted IL-18, we examined cytokine
expression in tissues of B16/P, B16/IL18, and IFN-g-neutralized
B16/IL18. First, we examined the Th1/Th2 cytokine pro®le in
these tissues using the RT-PCR method. As shown in Fig 7, IFN-
g mRNA was strongly expressed in B16/IL18 tissues, but not in
tissues of B16/P and IFN-g-neutralized B16/IL18. As IP-10 and
Mig are known to be produced in response to IFN-g and have been
reported to possess antiangiogenic activity, we examined the
expression of these two chemokines. We found IP-10 mRNA to
be strongly expressed in B16/IL18 tissues but not in tissues of B16/
P and anti-IFN-g-antibody-treated B16/IL18 like IFN-g mRNA.
Mig mRNA could be detected only in B16/IL18 tissues (Fig 7).
To con®rm which cells produce IFN-g, we performed
immunohistochemical staining with antimouse IFN-g mAb on
the tissue sections of B16/IL18. We con®rmed that in¯ammatory
cells accumulating around tumor cells produced IFN-g but the
tumor cells did not (Fig 8).
IP-10 and Mig expression in B16 melanoma cells treated
with IFN-g Melanoma cells are reported to have IFN-g
receptors; therefore we examined whether IP-10 and/or Mig
expression could be induced in B16 melanoma cells by treatment
with IFN-g. At ®rst, using a semiquantitative RT-PCR method,
we found that B16 melanoma cells did express mRNA of both IP-
10 and Mig, but not that of IFN-g, through treatment with IFN-g
in vitro (Fig 9). The absence of expression of IFN-g mRNA in vitro
was compatible with the results of immunohistochemical IFN-g
staining for B16/IL18 tumor tissue (Fig 8). There was no
Figure 4. In vivo neutralization of IFN-g partially abrogated the
antitumor effect of B16/IL18. B16/IL18 was challenged in IFN-g-
neutralized C57/BL6 mice. In vivo neutralization of IFN-g activity was
achieved as described in Materials and Methods. Mice were injected
subcutaneously with tumor cells (1 3 106) in the right ¯ank on day 0.
Tumor measurements were made as described in Fig 2. Data are
presented as mean values in tumor size of ®ve mice per group. Error
bars represent standard deviation. d, B16/IL18 in C57/BL6 mice; n,
B16/IL18 in IFN-g-neutralized C57/BL6 mice. *p < 0.05 (Student's t
test).
Figure 3. Depletion of CD8+ T or natural killer cells did not
affect the tumor growth of IL-18-secreting B16 melanoma cells.
Mice were injected subcutaneously with B16/IL18 cells (1 3 106) in the
right ¯ank on day 0. Tumor measurements were made as described in
Fig 2. The depletion of natural killer cells or CD8+ T cells was
performed as described in Materials and Methods. Data are presented as
mean values in tumor size of ®ve mice per group. Error bars represent
standard deviation. B16/IL18 in C57/BL6 mice; h, B16/IL18 in
natural-killer-cell-depleted C57/BL6 mice; n, B16/IL18 in CD8+ T-
cell-depleted C57/BL6 mice.
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difference in the expression levels of IP-10 and Mig between B16/
P and B16/IL18. Next, to examine whether both IP-10 and Mig
are secreted as proteins from B16 melanoma cells treated with IFN-
g, we performed a direct ELISA assay as described in Materials and
Methods. We found that B16 melanoma cells treated with IFN-g
secreted 42.5 ng per ml of IP-10 and 10.0 ng per ml of Mig into
supernatant per 106 cells per 24 h. The supernatants from untreated
B16F10 melanoma cells showed no detectable levels of IP-10 and
Mig.
The effect of IFN-g treatment on angiogenic factors in B16
melanoma cells Next, we investigated whether IFN-g affects
the expression of angiogenic factors, VEGF, and angiogenin, which
have been detected in melanoma cells (Hartmann et al, 1999;
Ugurel et al, 2001). As shown in Fig 10, the level of angiogenin
mRNA was clearly reduced in B16 melanoma cells treated with
IFN-g. The expression of VEGF mRNA was not affected by
treatment with IFN-g.
DISCUSSION
Despite several studies showing that introduction of the IL-18 gene
into cancer cells results in the retardation of tumor growth in vivo
(Tan et al, 1998; Tasaki et al, 2000), it is questionable whether IL-
18 is fully secreted from these tumor cells because the IL-18 gene
has no signal sequence for the secretion of this cytokine (Okamura
Figure 5. Inhibition of tumor vessel
formation and induction of tumor necrosis
in B16/IL18 tumors. A histologic analysis of the
tumor tissue 6 d after subcutaneous injection was
performed. Sections of B16/P tissues (a, d), B16/
IL18 tissues (b, e), and B16/IL18 tissues of IFN-g-
neutralized mice (c, f) were stained for HE (a, b, c)
and CD31 (d, e, f). Fixation was performed using
a zinc-based ®xative. Immuno- histochemical
staining was performed by an avidin±biotin
complex method as described in Materials and
Methods. Asterisks indicate necrosis. Scale bar:
200 mm.
Figure 6. Vascularization was markedly reduced in B16/IL18
tumors. Sections of tumor tissues 6 d after inoculation were stained for
CD31. Vascularization within the tumors was assessed by counting the
number of CD31-positive vessels per ®eld within the tumor except
necrotic areas. The counting was performed by two independent
observers. *p < 0.01, **p < 0.01; NS, not signi®cant.
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et al, 1995). Here we found that tumor cells transduced with
secreted-type modi®ed IL-18 cDNA, but not native IL-18 cDNA,
did secrete mature IL-18 into the supernatant. This ®nding
indicates that secretion of IL-18 from transfected cells requires a
signal sequence in the transduced cDNA. We also found that
transduction with secreted-type modi®ed IL-18 cDNA, but not
native IL-18, of B16F10 melanoma cells inhibited in vivo tumor
growth. This is in contrast to previous reports that showed an
antitumor effect of IL-18 transfection with native IL-18 cDNA
(Tan et al, 1998; Tasaki et al, 2000). Recently, Heuer et al (1999)
reported a similar ®nding: that neuroblastoma cells transduced with
a cDNA containing the IL-11 leader peptide sequence fused to the
mature IL-18 sequence, but not native IL-18, induced an antitumor
response. These observations strongly suggest that it is necessary for
the induction of an ef®cient antitumor response by IL-18 gene
transfer that mature IL-18 be secreted from the tumor cells. In this
study, we constructed hybrid cDNA consisting of an IFN-b signal
sequence and mature IL-18 sequence, and then succeeded in
inducing an ef®cient antitumor effect by transduction with the
hybrid cDNA into B16F10 melanoma cells. We believe that the
use of hybrid cDNA is one of the best ways to induce an effective
antitumor response when conducting gene therapy utilizing IL-18.
Although some reports have shown that systemic treatment with
IL-18 inhibited tumor growth, most of them were performed using
highly immunogenic tumor cells (Micallef et al, 1997). Previously,
we found that systemic administration of recombinant IL-18 did
not inhibit the growth of B16F10 melanoma, even at a maximun
dose of IL-18 (Nagai et al, 2000). This difference may be attributed
Figure 8. In¯ammatory cells accumulating around tumor cells
produced IFN-g but tumor cells did not. Frozen sections of B16/
IL18 tissues at day 6 were immunohistochemically stained with
antimouse IFN-g mAb. Immunohistochemical staining was performed
with an avidin±biotin complex as described in Materials and Methods.
Arrows indicate positive signals. Scale bar: 50 mm.
Figure 7. IFN-g, IP-10, and Mig were expressed in B16/IL18
tissues. Tumor cells (1 3 106) in PBS were subcutaneously inoculated
into the right ¯ank of syngeneic mice. After 6 d, whole tumor tissues
were resected and homogenized using a sonicator. Then, total cellular
RNA was extracted from each sample. To examine the Th1/Th2
cytokine pro®le, we used the RT-Multiplex PCR system, by which
multiple ampli®ed targets can be detected under the same conditions.
P.C., positive control; glyceraldehyde-3-phosphate dehydrogenase, IL-4,
IL-10, IFN-g, and IL-2 were detected. To examine the expression of
IP-10 and Mig, the usual semiquantitative RT-PCR was performed with
the primer pairs described in Materials and Methods.
Figure 9. B16 melanoma cells expressed IP-
10 and Mig in response to IFN-g. Cells were
cultured in the presence (200 and 1000 U per ml)
or absence of recombinant murine IFN-g for
24 h. Total cellular RNA was extracted from B16
melanoma cells after IFN-g treatment. Expression
levels of IP-10 and Mig in B16 melanoma cells
were analyzed using the RT-PCR method. b-
actin was used as an inner control.
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to the poor immunogenicity of B16F10 melanoma cells. As shown
in Fig 2, however, the transfer of a modi®ed secreted-type IL-18
gene to B16F10 cells enabled the suppression of tumor growth
in vivo without any adverse effects. We believe that continuing local
IL-18 secretion is extremely important for inducing ef®cient
antitumor effects on B16F10 melanoma, which is poorly
immunogenic by nature.
The antitumor effect of IL-18 in this study was expected to have
been mediated through T cells and/or natural killer cells, because
IL-18 has been shown to activate T cells and natural killer cells
in vitro (Okamura et al, 1995). To our surprise, however, in vivo
depletion of CD8+ T cells as well as natural killer cells did not affect
the tumor growth of IL-18-producing B16F10 melanoma. This
means that T-cell- and natural-killer-cell-mediated immune
responses seem to be a minor part of the mechanisms inhibiting
melanoma growth under the conditions used in this study. A similar
observation was made by Coughlin et al (1998a) who showed that
the growth of IL-18-transduced mammary carcinoma was not
mediated by protective immunity. In contrast, the antitumor effect
of B16F10 melanoma transduced with IL-12 cDNAs was partially
mediated through natural killer cells as well as CD8+ T cells, which
was con®rmed by an in vivo depletion assay (Nagai et al, 2000). The
mechanism of the in vivo antitumor effect on B16 melanoma by
local secretion thus differs between IL-12 and IL-18, although these
cytokines have similar biologic activity.
Here we showed that the expression of IFN-g induced by IL-18
secreted from tumor cells contributed to the inhibition of tumor
vessel formation. Cao et al (1999) has shown that in vivo IL-18
administration suppressed the growth of ®brosarcoma via anti-
angiogenic activity. Because anti-IFN-g treatment abolished the
antitumor effect as well as antiangiogenic activity in our study, the
main pathway of the antiangiogenic activity of IL-18 seems to be
controlled by IFN-g. It has been shown that the gene transfer of
IFN-g into brain tumor represses the growth of the tumor via an
antiangiogenic effect (Fathallah Shaykh et al, 2000). IFN-g thus
plays an important role in the antitumor effect of IL-18 through its
antiangiogenic activity. As IFN-g is known to induce the
expression of IP-10 and Mig (Luster and Ravetch, 1987; Liao et
al, 1995), we further investigated whether these cytokines are
involved in the antiangiogenic effect of the IL-18 transfectant. We
found that IP-10 and Mig were produced, and that their induction
paralleled that of IFN-g in IL-18-secreting tumor tissues. IP-10 and
Mig have been reported to exhibit potent antiangiogenic activity
in vitro and in vivo (Angiolillo et al, 1995; Strieter et al, 1995a;
Farber, 1997). Strieter et al (1995a) showed that CXC chemokines
possessing an ELR amino acid motif immediately preceding the
CXC motif are angiogenic agents, whereas those that do not have
the ELR motif are angiogenic inhibitors. Interestingly, a balance in
the expression of ELR+ and ELR± CXC chemokines within tumor
tissue has been proposed as an important determinant of progressive
tumor growth and metastasis (Strieter et al, 1995b). Actually, IP-10
and Mig have this ELR amino acid motif immediately preceding
the CXC motif. Both chemokines have been reported to cause
focal tumor necrosis associated with extensive vascular damage
when injected intratumorally or when expressed by tumor cells
(Sgadari et al, 1996; 1997). Furthermore, Arenberg et al (1996)
showed that IP-10 expression by human lung tumors in SCID mice
is associated with reduced tumor growth potential, whereas
neutralization of IP-10 enhances growth. Such evidence indicates
that IP-10 and Mig, which are inducible by IFN-g stimulation, play
an important role in the inhibition of tumor angiogenesis. We
strongly suggest that the antitumor effect of the modi®ed IL-18
gene used in this study was partly due to the antiangiogenic activity
of IP-10 and Mig.
We also demonstrated that B16 melanoma cells expressed both
IP-10 and Mig in the presence of IFN-g (Fig 9). It has been
believed that B16 melanoma cells do not express IP-10 or Mig
constitutively (Asselin-Paturel et al, 1998). We ®rst showed here
that B16 melanoma cells did produce IP-10 and Mig by means of
RT-PCR and direct ELISA methods. It has been described that the
responsiveness to IFN-g of the tumor cells determines if the tumor
shows IFN-g-induced antiangiogenic activity, because tumors with
a dominant negative IFN-g receptor gene show retarded
antiangiogenic activity (Coughlin et al, 1998b). We therefore
suggest that the production of IP-10 and Mig by B16 melanoma
cells in response to IFN-g is critical to the induction of
antiangiogenic activity induced by IL-18. It is of interest that
B16 melanoma cells were forced to produce IP-10 and Mig in
response to IFN-g, because these cytokines are not favorable for
tumor survival. In addition, we also showed that the expression of
angiogenin, which is one of the angiogenic factors of melanoma
(Ugurel et al, 2001), was reduced in B16F10 melanoma cells by
IFN-g treatment. VEGF expression was not affected by IFN-g in
B16F10 melanoma cells, although it has been reported that IFN-g
reduced VEGF production in a murine breast cancer model in vitro
(Dias et al, 1998). We believe that the downregulation of
angiogenic factor is another important mechanism in the
antiangiogenic effect of IFN-g on B16F10 melanoma.
In conclusion, our results indicate that gene transfer of secreted-
type IL-18 to B16F10 melanoma cells is a useful method that
produces an antitumor response without any systemic adverse
effects and that the antitumor ef®cacy is mainly mediated by
antiangiogenic activity through IFN-g. The antiangiogenic activity
was possibly involved in at least two dynamic changes induced by
IFN-g inside B16 melanoma cells; one was the upregulation of
antiangiogenic chemokines, IP-10 and Mig; the other was the
downregulation of angiogenic factor, angiogenin. IL-18 is a
potential candidate for use in gene therapy for malignant
melanoma.
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Figure 10. IFN-g reduced the expression of angiogenin in B16
melanoma cells. Cells were cultured in the presence (2000 U per ml)
or absence of recombinant murine IFN-g for 24 h. Total cellular RNA
was extracted from B16 melanoma cells after IFN-g treatment.
Expression levels of VEGF and angiogenin in B16 melanoma cells were
analyzed using the semiquantative RT-PCR method. b-actin was used as
an inner control. N.C., negative control.
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